What is the most common subtype of Human Papillomavirus (HPV) associated with cervical cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Most Common HPV Subtype in Cervical Cancer

HPV type 16 is the most common subtype associated with cervical cancer, accounting for approximately 55-60% of all cervical cancers worldwide. 1

HPV Type Distribution in Cervical Cancer

Primary Oncogenic Types

  • HPV 16 is the single most carcinogenic genotype, responsible for 50-60% of invasive squamous cell carcinomas globally and approximately 40% of adenocarcinomas 1

  • HPV 18 is the second most common type, accounting for 10-15% of all cervical cancers 1

  • Together, HPV types 16 and 18 cause approximately 68-70% of all cervical cancers worldwide, including 68% of squamous cell cancers and 83% of adenocarcinomas 1, 2, 3

Clinical Significance of HPV 16

  • HPV 16 demonstrates unique aggressive characteristics: it is the most prevalent type in CIN3 lesions, most likely to persist after infection, and has the highest probability of progressing to CIN3 when persistent 1

  • The 10-year cumulative incidence of CIN3 or worse is 17.2% for HPV16-positive women, compared to only 3.0% for women positive for other oncogenic HPV types 4

  • HPV 16 persistence (one-year or two-year) strongly predicts a 20-30% risk of CIN3+ over 5 years 1

Other Contributing HPV Types

  • Approximately 10 other high-risk HPV genotypes (including types 31,33,35,39,45,51,52,56,58,59,68,73, and 82) collectively cause the remaining 25-35% of cervical cancers 1, 5

  • HPV 18 causes a disproportionately higher percentage of adenocarcinomas (approximately 32%) compared to squamous cell carcinomas (8%) 1

Key Clinical Implications

Vaccine Impact

  • Prophylactic vaccines targeting HPV 16/18 have the potential to prevent more than two-thirds of worldwide cervical carcinomas and approximately 80.9% of HPV-positive cervical cancers 2

Detection and Screening

  • Nearly 100% of cervical cancer cases test positive for HPV, with HPV detected in 99% of all cervical tumors 2, 6

  • Individual identification of HPV 16 or 18 in clinical practice may effectively stratify women at particularly high risk for aggressive management, as opposed to pooled oncogenic HPV testing alone 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.